Doubling Armour Thyroid from 30 mg to 60 mg is appropriate and follows standard dosing protocols
The dose increase from 30 mg to 60 mg Armour Thyroid is within recommended guidelines, as the usual starting dose is 30 mg with increments of 15 mg every 2-3 weeks, and most patients require 60-120 mg daily for adequate replacement 1.
Dosing Algorithm
The FDA-approved dosing for Armour Thyroid follows this structure 1:
- Starting dose: 30 mg daily (15 mg if cardiovascular disease or long-standing myxedema)
- Titration: Increase by 15 mg every 2-3 weeks
- Maintenance range: 60-120 mg daily for most patients
- Maximum consideration: Doses up to 180 mg may be needed, though failure to respond suggests non-compliance or malabsorption
Your patient's increase to 60 mg represents a single 30 mg increment, which is reasonable but slightly larger than the recommended 15 mg increments. This is still acceptable practice.
Critical Monitoring Requirements
Check TSH 4-8 weeks after this dose change 2. Do not adjust dosing more frequently, as thyroid hormone levels take this long to plateau, particularly with smaller starting doses.
Key Laboratory Targets:
- TSH normalization is the primary endpoint for primary hypothyroidism
- Expect elevated T3 levels with desiccated thyroid - this is characteristic of the medication 3, 4
- T4 levels will be lower than with levothyroxine monotherapy 3, 4
Important Safety Considerations
Cardiovascular Monitoring
Watch for cardiac symptoms, particularly 1:
- New or worsening angina
- Palpitations
- Tachycardia
- Excessive sweating
If angina develops, reduce the dose immediately - this is an absolute indication for dose reduction 1.
Special Populations Requiring Caution
- Age >50-60 years: Consider slower titration
- Known coronary disease: Should have started at 15 mg, not 30 mg
- Elderly patients: Often require 20-25% less per kilogram than younger patients 2
Desiccated Thyroid Specific Issues
Pharmacologic Concerns
Desiccated thyroid produces a 4:1 ratio of T4:T3 5, resulting in:
- Supraphysiologic T3 peaks after dosing 3
- Lower steady-state T4 levels 4
- Potential for thyrotoxic symptoms even when TSH is normal 3
The elevated T3 levels can cause symptoms in some patients and may misleadingly suggest inadequate dosing when T4 is measured 3.
Product Consistency Warning
Desiccated thyroid remains outside formal FDA oversight for consistency 5. Manufacturers monitor T3/T4 content, but batch-to-batch variability exists. This is a significant limitation compared to synthetic levothyroxine.
When to Reassess Treatment Choice
Consider switching to levothyroxine if 3, 6:
- Patient develops thyrotoxic symptoms (tremor, palpitations, anxiety)
- Cardiovascular concerns arise
- T3 levels are consistently supraphysiologic
- Patient has other risk factors for hypercoagulability
Follow-up Timeline
4-8 weeks post-dose change 2:
- Check TSH, free T4, total T3
- Assess symptoms
- Evaluate for signs of over-replacement
Once stable 2:
- Monitor TSH every 6 months initially
- Then annually if consistently stable
The 60 mg dose is appropriate as a next step, but requires proper monitoring and awareness of desiccated thyroid's unique pharmacologic profile.